×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Clinical: DNL628 Phase 1 AD Trial (NCT07328451) — Denali Tau ASO
clinical
917 words
KG: ent-clin-6be0ce87
Contents
DNL628 Phase 1 AD Trial (NCT07328451) — Denali Tau ASO
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (10)
Phase-Separated Organelle Targeting
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Lysosomal Enzyme Trafficking Correction
Score: 0.71
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
Synaptic Vesicle Tau Capture Inhibition
Score: 0.58
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.57
Lysosomal Membrane Repair Enhancement
Score: 0.54
Blood-Brain Barrier SPM Shuttle System
Score: 0.53
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.48
Related Analyses (4)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Related Experiments (7)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40
Tau ASO Therapy
validation · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Show 2 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)